Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Seeking Alpha News (Fri, 31-Jan 6:47 AM ET)
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Globe Newswire (Wed, 29-Jan 8:00 AM ET)
Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
TipRanks (Mon, 27-Jan 5:15 AM ET)
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Globe Newswire (Mon, 13-Jan 7:00 AM ET)
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 8-Jan 8:30 AM ET)
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
Globe Newswire (Tue, 7-Jan 8:00 AM ET)
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
Globe Newswire (Mon, 9-Dec 12:00 PM ET)
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
Globe Newswire (Thu, 14-Nov 8:30 AM ET)
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Globe Newswire (Thu, 7-Nov 8:00 AM ET)
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Globe Newswire (Tue, 5-Nov 9:01 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of January 31, 2025, CRSP stock price climbed to $42.29 with 828,910 million shares trading.
CRSP has a beta of 1.78, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.21 to the broad based SPY ETF.
CRSP has a market cap of $3.61 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $602,000 in Revenue and -$1.01 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.41.
In the last 3 years, CRSP traded as high as $91.10 and as low as $36.52.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, ARKG, XBI, VXF, IBB.
CRSP has underperformed the market in the last year with a return of -34.4%, while the SPY ETF gained +25.5%. In the last 3 month period, CRSP fell short of the market, returning -11.8%, while SPY returned +5.4%. However, in the most recent 2 weeks CRSP has outperformed the stock market by returning +4.9%, while SPY returned +3.0%.
CRSP support price is $40.58 and resistance is $43.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.